GeneDx Holdings Corp. plans to add long-read whole genome sequencing (lrWGS) to its testing portfolio to improve rare-disease diagnosis. The technology is designed to identify complex genetic variations that traditional short-read sequencing often misses. By integrating lrWGS with its GeneDx Infinity platform, the company expects to provide more comprehensive and accurate diagnostic answers and potentially shorten the time to diagnosis.
The move builds on GeneDx’s clinical expertise and phenotype-driven approach to interpreting genomic data. The enhancement is expected to help resolve complex genetic cases. GeneDx shares had risen the day before the announcement; an immediate market reaction was not widely reported.